Cancer-Associated Thrombosis — Part 2: VTE Prophylaxis in Cancer Patients

Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.

guidelines•Mar 2026•guidelines

VTE Prophylaxis in Ambulatory Cancer Patients

General Principles

The majority of cancer-associated VTE events occur in the outpatient setting during systemic anticancer therapy. Routine pharmacologic thromboprophylaxis for all ambulatory cancer patients is not recommended due to the overall modest absolute VTE risk, the bleeding risk associated with anticoagulation, patient burden, and cost. Instead, a risk-stratified approach is endorsed by the major guideline panels.1 2 3

Recommendations for Ambulatory Patients Receiving Systemic Therapy

Risk Assessment Before Prophylaxis

The expert panels recommend:

  1. All patients starting a new systemic anticancer regimen should undergo VTE risk assessment using a validated risk assessment model, preferably the Khorana score.1 2

  2. Patients with a Khorana score of ≥ 2 may be considered for pharmacologic thromboprophylaxis, provided bleeding risk is acceptable and there are no significant drug interactions.1

  3. Risk reassessment should occur at the time of treatment change, disease progression, hospitalization, or new development of risk factors (new immobility, new central venous catheter).1 2

Thromboprophylaxis Options for High-Risk Ambulatory Patients

For ambulatory cancer patients with a Khorana score ≥ 2 (or otherwise judged high-risk) who do not have active bleeding or high bleeding risk:

AgentDoseEvidence Base
Apixaban2.5 mg orally twice dailyAVERT trial4
Rivaroxaban10 mg orally once dailyCASSINI trial5
Low-molecular-weight heparin (LMWH)Varies by agent (see dosing table below)PROTECHT, SAVE-ONCO trials6 7

Preferred agents: The oncology clinical guideline committees express a preference for direct oral anticoagulants (DOACs) — specifically apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily — for primary thromboprophylaxis in high-risk ambulatory patients, based on oral convenience, patient acceptance, and favorable trial data.1 2 3

Key Trial Data for Ambulatory Prophylaxis

AVERT Trial (Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients)
ParameterDetail
DesignRandomized, double-blind, placebo-controlled
Population574 ambulatory cancer patients initiating chemotherapy, Khorana score ≥ 2
InterventionApixaban 2.5 mg BID vs. placebo for 180 days
Primary outcome (VTE)4.2% apixaban vs. 10.2% placebo (HR 0.41; 95% CI, 0.26-0.65; p < 0.001)
Major bleeding3.5% apixaban vs. 1.8% placebo (HR 2.00; 95% CI, 1.01-3.95)
Net clinical benefitFavored apixaban
Key conclusionApixaban significantly reduced VTE in high-risk ambulatory cancer patients, with a modest increase in major bleeding4
CASSINI Trial (Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Cancer Patients)
ParameterDetail
DesignRandomized, double-blind, placebo-controlled
Population841 ambulatory cancer patients initiating chemotherapy, Khorana score ≥ 2
InterventionRivaroxaban 10 mg daily vs. placebo for 180 days
Primary outcome (VTE) — intention to treat6.0% rivaroxaban vs. 8.8% placebo (HR 0.66; 95% CI, 0.40-1.09; p = 0.10) — not statistically significant
Primary outcome — on-treatment analysis2.6% rivaroxaban vs. 6.4% placebo (HR 0.40; 95% CI, 0.20-0.80) — significant
Major bleeding2.0% rivaroxaban vs. 1.0% placebo (not significant)
Key conclusionRivaroxaban did not reach significance in the ITT analysis but showed significant VTE reduction in the on-treatment period; interpretation limited by high rate of early treatment discontinuation in the intervention arm5
PROTECHT Trial (Prophylaxis of Thromboembolism during Chemotherapy)
ParameterDetail
DesignRandomized, double-blind, placebo-controlled
Population1,150 ambulatory cancer patients receiving chemotherapy
InterventionNadroparin 3,800 IU daily vs. placebo
Primary outcome (VTE + arterial TE)2.0% nadroparin vs. 3.9% placebo (p = 0.02)
Major bleedingNo significant difference
Key conclusionNadroparin reduced composite thromboembolic events in ambulatory cancer patients6
SAVE-ONCO Trial
ParameterDetail
DesignRandomized, double-blind, placebo-controlled
Population3,212 patients with locally advanced or metastatic cancer receiving chemotherapy
InterventionSemuloparin (ultra-LMWH) 20 mg daily vs. placebo
Primary outcome (VTE)1.2% semuloparin vs. 3.4% placebo (HR 0.36; 95% CI, 0.21-0.60; p < 0.001)
Major bleeding1.2% vs. 1.1% (no significant difference)
Key conclusionSemuloparin significantly reduced VTE without increased major bleeding; however, semuloparin is not commercially available7

Duration of Ambulatory Prophylaxis

  • When initiated, ambulatory thromboprophylaxis should continue for the duration of systemic anticancer therapy or up to 6 months, whichever comes first.1 2
  • Reassessment of the risk-benefit balance should occur at regular intervals, particularly at treatment change points.1
  • There is no established role for indefinite prophylaxis beyond the active treatment period in the absence of a VTE event.2

VTE Prophylaxis in Hospitalized Cancer Patients

General Principles

Hospitalized cancer patients are at substantially elevated VTE risk due to the combination of acute illness, immobility, surgery, and the underlying cancer-associated prothrombotic state. Most hospitalized cancer patients should receive pharmacologic thromboprophylaxis unless contraindicated.1 2 3

Recommendations

  1. Hospitalized cancer patients with an acute medical illness or reduced mobility should receive pharmacologic thromboprophylaxis with LMWH, low-dose unfractionated heparin (UFH), or fondaparinux throughout the hospital stay, unless active bleeding, high bleeding risk, or other contraindications are present.1 2 3

  2. Hospitalized cancer patients who are ambulatory and admitted solely for minor procedures or short chemotherapy infusions may not require routine thromboprophylaxis if they remain fully ambulatory and the hospitalization duration is short (< 24-48 hours).1

  3. Mechanical prophylaxis (intermittent pneumatic compression devices) should be used in addition to pharmacologic prophylaxis, or as sole prophylaxis when pharmacologic agents are contraindicated.2

Dosing for Hospitalized Medical Cancer Patients

AgentProphylactic Dose
Enoxaparin40 mg subcutaneously once daily
Dalteparin5,000 IU subcutaneously once daily
Tinzaparin4,500 IU (or 75 IU/kg) subcutaneously once daily
Unfractionated heparin (UFH)5,000 units subcutaneously every 8-12 hours
Fondaparinux2.5 mg subcutaneously once daily

Extended Post-Discharge Prophylaxis for Medical Patients

  • Routine extended post-discharge thromboprophylaxis is not recommended for the majority of hospitalized medical cancer patients, based on data from the MAGELLAN, MARINER, and APEX trials that showed an unfavorable benefit-risk ratio in the overall hospitalized medical population.1 2
  • Selected high-risk patients (those with additional VTE risk factors, prolonged immobility, or very high Khorana scores) may benefit from post-discharge prophylaxis for an additional 2-4 weeks. This decision should be individualized.2

Surgical Thromboprophylaxis in Cancer Patients

General Principles

Cancer patients undergoing surgical procedures are at markedly elevated VTE risk — approximately two-fold higher than non-cancer surgical patients. All major guidelines strongly recommend pharmacologic thromboprophylaxis for cancer patients undergoing major surgery.1 2 3 8

Preoperative and Perioperative Recommendations

  1. All cancer patients undergoing major surgical procedures (including major abdominal, pelvic, thoracic, or orthopedic surgery) should receive pharmacologic thromboprophylaxis with LMWH or low-dose UFH, starting preoperatively or as soon as feasible postoperatively, unless contraindicated by active bleeding or very high bleeding risk.1 8

  2. LMWH is preferred over UFH for surgical thromboprophylaxis in cancer patients based on evidence of superior efficacy in this population.1 8

  3. Mechanical prophylaxis (intermittent pneumatic compression, graduated compression stockings) should be used as an adjunct to pharmacologic prophylaxis and as sole prophylaxis when pharmacologic agents are contraindicated.8

  4. Timing of initiation: LMWH may be started 2-12 hours preoperatively or 6-12 hours postoperatively, depending on surgical bleeding risk and institutional protocol. UFH is typically started 2 hours preoperatively or 6-12 hours postoperatively.8

Surgical Prophylaxis Dosing

AgentDoseTiming
Enoxaparin40 mg SC once dailyStart 2-12 h preop or 6-12 h postop
Dalteparin2,500-5,000 IU SC once dailyStart 2-4 h preop (2,500 IU) then 5,000 IU daily or start 5,000 IU 8-12 h postop
Tinzaparin3,500-4,500 IU SC once dailyStart 2 h preop or 6-12 h postop
UFH5,000 units SC every 8 hoursStart 2 h preop or 6-12 h postop
Fondaparinux2.5 mg SC once dailyStart 6-8 h postop

Duration of Surgical Prophylaxis

Surgery TypeRecommended Duration
Major abdominal or pelvic cancer surgeryExtended duration: 4 weeks (28 days) postoperatively
Major thoracic cancer surgery4 weeks recommended; minimum 7-10 days if bleeding risk is high
Other major cancer surgeryMinimum 7-10 days; extended to 4 weeks when feasible
Laparoscopic surgery (duration > 30 minutes, non-minor)At least 7-10 days; extended prophylaxis considered for high-risk patients

Key evidence for extended surgical prophylaxis: The ENOXACAN II trial demonstrated that extended-duration (4-week) enoxaparin following major abdominal cancer surgery reduced VTE from 12.0% to 4.8% (p = 0.02) compared with 1-week prophylaxis, without a significant increase in bleeding. This finding established the standard of 4-week post-operative prophylaxis for major abdominal/pelvic cancer surgery.9

Neuraxial Anesthesia Considerations

  • When neuraxial anesthesia (epidural or spinal) is planned, LMWH should be held for at least 12 hours before catheter placement and for 4 hours after catheter removal.8
  • UFH should be held for 4-6 hours before catheter placement.8
  • These intervals must be coordinated between the surgical, anesthesia, and pharmacy teams.8

Thromboprophylaxis in Multiple Myeloma

Multiple myeloma patients receiving immunomodulatory drug (IMiD)-based regimens represent a unique high-risk population for VTE that warrants specific consideration outside of the standard Khorana score framework.1 2

Risk Stratification for Myeloma Patients on IMiD Regimens

Risk CategoryPatient/Treatment CharacteristicsRecommended Prophylaxis
Standard risk (≤ 1 myeloma VTE risk factor)IMiD-based regimen without high-risk featuresAspirin 81-325 mg daily
High risk (≥ 2 myeloma VTE risk factors)Prior VTE, immobility, obesity, concurrent high-dose dexamethasone, concurrent doxorubicin, concurrent erythropoietic agents, inherited thrombophilia, central venous catheter, comorbidities (cardiac disease, diabetes, renal disease, infection)LMWH (enoxaparin 40 mg daily) or full-dose warfarin (INR 2-3) or DOAC

Myeloma-Specific VTE Risk Factors

Risk Factor CategoryExamples
IndividualPrior VTE, obesity (BMI ≥ 30), central venous catheter, comorbidities (cardiac, renal, diabetes), immobility, inherited thrombophilia, recent surgery, erythropoietic agents
Myeloma-relatedDiagnosis itself, hyperviscosity, high tumor burden
Treatment-relatedHigh-dose dexamethasone (≥ 480 mg/month), doxorubicin, multi-agent chemotherapy

Duration

  • Thromboprophylaxis in myeloma should continue for the duration of IMiD-based therapy.1 2
  • If high-dose dexamethasone is reduced to low-dose maintenance, individual reassessment of continued need is appropriate.2

Epidemiology

Central venous access device (CVAD)-related thrombosis occurs in 0.3-28% of cancer patients with CVADs, depending on detection method (symptomatic vs. screening ultrasonography), catheter type, insertion site, and patient-specific risk factors.10 11

CategoryRisk Factors
Patient-relatedPrior VTE, hypercoagulable state, advanced cancer stage, high BMI, poor performance status, dehydration
Catheter-relatedLarger catheter gauge, multiple lumens, peripherally inserted central catheters (PICCs) vs. tunneled catheters, left-sided insertion, catheter malposition (tip not at cavoatrial junction)
Insertion-relatedMultiple insertion attempts, subclavian vein insertion (vs. internal jugular), non-ultrasound-guided insertion, operator inexperience
Treatment-relatedCertain chemotherapy regimens (particularly vesicants), parenteral nutrition, blood product administration, frequent blood draws

Catheter Tip Position

Optimal catheter tip position at the cavoatrial junction (junction of the SVC and right atrium) or in the lower third of the SVC is associated with the lowest rates of CVAD-related thrombosis. Malpositioned catheters (tip in the upper SVC, brachiocephalic vein, or subclavian vein) are at substantially higher thrombotic risk.10 11

Routine anticoagulant prophylaxis is NOT recommended for the sole purpose of preventing CVAD-related thrombosis. Multiple randomized trials and meta-analyses have failed to demonstrate a consistent benefit of prophylactic-dose anticoagulation specifically for CVAD-related VTE prevention.1 2 3 10

Key evidence:

Trial/StudyInterventionResult
Meta-analysis of low-dose warfarin for CVAD prophylaxisWarfarin 1 mg dailyNo significant reduction in CVAD-related thrombosis
Meta-analysis of prophylactic LMWH for CVADLMWH at prophylactic dosesNo significant reduction in CVAD-related thrombosis
Systematic review (Cochrane)Various anticoagulantsInsufficient evidence to support routine prophylaxis for CVAD-related thrombosis

Non-Pharmacologic Prevention Strategies

The following measures are recommended to minimize CVAD-related thrombosis risk:10 11

  1. Ultrasound-guided insertion to minimize vessel trauma and ensure first-pass success.
  2. Right internal jugular vein access preferred when feasible (most direct anatomical course to the SVC; associated with lower thrombosis rates than subclavian or PICC insertion).
  3. Smallest gauge catheter with fewest lumens appropriate for the clinical indication.
  4. Catheter tip confirmation at the cavoatrial junction using intraoperative fluoroscopy, intracavitary ECG, or post-procedure imaging.
  5. Avoid PICC lines when a tunneled catheter or implanted port is appropriate for the expected treatment duration and frequency. PICCs are associated with higher rates of upper extremity DVT compared with tunneled central catheters and ports, particularly in cancer patients.10
  6. Prompt removal of CVADs that are no longer clinically necessary.
  7. Adequate catheter care and flushing per institutional protocol to maintain patency and minimize fibrin sheath formation.

Special Prophylaxis Considerations

Immune Checkpoint Inhibitor-Associated VTE

Emerging data suggest that immune checkpoint inhibitors (ICIs) — including anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atezolizumab, durvalumab), and anti-CTLA-4 (ipilimumab) agents — may be associated with increased VTE risk. Reported VTE incidence ranges from 3-13% across retrospective series.12

  • The mechanism may involve ICI-mediated immune activation, inflammation, and endothelial dysfunction.12
  • Current guidelines do not recommend routine thromboprophylaxis for patients receiving ICIs as monotherapy. However, clinicians should maintain vigilance for VTE and consider prophylaxis in patients with additional risk factors.1 2

Hormonal Therapy

  • Tamoxifen: VTE risk is increased approximately 2-3 fold. Routine thromboprophylaxis is not recommended, but awareness of the additive risk with other factors is important.1
  • Aromatase inhibitors: Lower VTE risk than tamoxifen. No specific prophylaxis recommendation.1

Erythropoiesis-Stimulating Agents (ESAs)

  • Use of ESAs (epoetin alfa, darbepoetin alfa) is associated with a 1.5-2 fold increased VTE risk in cancer patients.1
  • ESAs should be used only when indicated (chemotherapy-induced anemia with hemoglobin < 10 g/dL), and the additional VTE risk should be factored into the overall risk assessment.1
  • When ESAs are used in patients already at high VTE risk, consideration of thromboprophylaxis is appropriate.1 2

Summary of Prophylaxis Recommendations

Clinical SettingRecommendationStrength
Ambulatory cancer patients — low risk (Khorana 0-1)Routine prophylaxis not recommendedStrong
Ambulatory cancer patients — high risk (Khorana ≥ 2)Consider apixaban 2.5 mg BID or rivaroxaban 10 mg dailyModerate
Hospitalized medical cancer patientsLMWH, UFH, or fondaparinux during hospitalizationStrong
Post-discharge (medical hospitalization)Routine extended prophylaxis not recommended; individualizeWeak
Major abdominal/pelvic cancer surgeryLMWH extended to 4 weeks postoperativelyStrong
Major thoracic or other cancer surgeryMinimum 7-10 days; consider 4 weeksModerate
Multiple myeloma on IMiD regimensRisk-adapted: aspirin for standard risk; LMWH, warfarin, or DOAC for high riskModerate
CVAD-related thrombosis preventionRoutine anticoagulant prophylaxis not recommended; optimize catheter selection and placementStrong

References

  1. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063-3071. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  2. Falanga A, Palumbo JS, Rickles FR, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(4):371-389. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  3. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  4. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711-719. (AVERT trial) ↩︎ ↩︎

  5. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720-728. (CASSINI trial) ↩︎ ↩︎

  6. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-949. (PROTECHT trial) ↩︎ ↩︎

  7. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609. (SAVE-ONCO trial) ↩︎ ↩︎

  8. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545-e608. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  9. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-980. (ENOXACAN II trial) ↩︎

  10. National Comprehensive Cancer Network. Cancer-Associated Venous Thromboembolic Disease, Version 1.2024. NCCN Clinical Practice Guidelines in Oncology. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  11. Wall C, Moore J, Thachil J. Catheter-related thrombosis: a practical approach. J Intensive Care Soc. 2016;17(2):160-167. ↩︎ ↩︎ ↩︎

  12. Moik F, Chan WSE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137(12):1669-1678. ↩︎ ↩︎